Cerdulatinib for the treatment of b-cell malignancies
Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a B-cell malignancy, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) or other transformed FL and/or have relapsed or not responded to a prior chemotherapy.
1. A method of treating a follicular lymphoma in a human patient in need thereof, comprising administering to the patient about 15 mg or about 30 mg of cerdulatinib or a pharmaceutically acceptable salt thereof twice daily, or about 30 mg of cerdulatinib or a pharmaceutically acceptable salt thereof once daily, wherein the cerdulatinib is administered as a monotherapy and not administered in combination with another anticancer drug therapy.
2. The method of claim 1 , wherein the follicular lymphoma is relapsed or refractory.
3. The method of claim 1 , wherein the follicular lymphoma is transformed follicular lymphoma.
4. The method of claim 1 , wherein the patient was previously administered a drug selected from the group consisting of an alkylating agent, an anti-CD20 antibody, a BCL-2 inhibitor, a BTK inhibitor, a P13Kδ inhibitor, a platinum-based drug, an antimetabolite, an anthracycline, a BCR pathway inhibitor, and another chemotherapeutic agent used for treating a follicular lymphoma.
5. The method of claim 1 , wherein the patient was previously administered a drug selected from the group consisting of venetoclax, rituximab, ibrutinib, idelalisib, and fludarabine.
6. The method of claim 1 , wherein the cerdulatinib is administered in a pharmaceutical composition further comprising a pharmaceutically acceptable excipient or carrier.
7. The method of claim 1 , wherein the patient has a mutation linked to relapse or a resistance to a drug for treating a follicular lymphoma, wherein the mutation is a del17p mutation, a P53 mutation, an ATM mutation, a STAT mutation, a STAT 6 mutation, a C481S STAT6 mutation, a mutation associated with the NOTCH pathway, a mutation associated with the Cadherin pathway, or a combination thereof.
8. The method of claim 1 , wherein the patient was previously administered a drug selected from the group consisting of venetoclax, rituximab, ibrutinib, idelalisib, fludarabine, R-CHOP (Rituximab; Cyclophosphamide; Doxorubicin hydrochloride; Oncovin (vincristine); Prednisone, R-CVP (Rituximab; Cyclophosphamide; Vincristine; Prednisone), bevacizumab, a combination of fludarabine and rituximab, a combination of bendamustine and rituximab, and a combination of bevacizumab and rituximab.
9. The method of claim 1 , wherein the patient is 60 years or older and relapsed after a first line cancer therapy.
10. The method of claim 1 , wherein the patient was previously administered a once daily a dose of about 45 mg of cerdulatinib or a pharmaceutically acceptable salt thereof and showed fatigue.